Deeper Knowledge, Faster

  • Analyze global market entry opportunities
  • Uncover prior art in expired and abandoned patents
  • Obtain formulation and manufacturing information
➤ Start Trial

or, See Plans & Pricing

Upgrade to enjoy subscriber-only features like email alerts and data export. See the Plans and Pricing

Serving leading biopharmaceutical companies globally:

Chinese Patent Office
Queensland Health
US Department of Justice
Federal Trade Commission
McKesson
UBS
Daiichi Sankyo
Boehringer Ingelheim
Accenture
Cipla

Generated: January 21, 2018

DrugPatentWatch Database Preview

ZETONNA Drug Profile

« Back to Dashboard

When do Zetonna patents expire, and when can generic versions of Zetonna launch?

Zetonna is a drug marketed by Astrazeneca Pharms and is included in one NDA. There are five patents protecting this drug.

This drug has one hundred and two patent family members in thirty-nine countries.

The generic ingredient in ZETONNA is ciclesonide. There are seven drug master file entries for this compound. Two suppliers are listed for this compound. Additional details are available on the ciclesonide profile page.

US Patents and Regulatory Information for ZETONNA

Applicant Tradename Generic Name Dosage NDA Approval Date TE Type RLD RS Patent No. Patent Expiration Product Substance Delist Req. Exclusivity Expiration
Astrazeneca Pharms ZETONNA ciclesonide AEROSOL, METERED;NASAL 202129-001 Jan 20, 2012 RX Yes Yes ➤ Subscribe ➤ Subscribe Y ➤ Subscribe
Astrazeneca Pharms ZETONNA ciclesonide AEROSOL, METERED;NASAL 202129-001 Jan 20, 2012 RX Yes Yes ➤ Subscribe ➤ Subscribe ➤ Subscribe
Astrazeneca Pharms ZETONNA ciclesonide AEROSOL, METERED;NASAL 202129-001 Jan 20, 2012 RX Yes Yes ➤ Subscribe ➤ Subscribe Y ➤ Subscribe
Astrazeneca Pharms ZETONNA ciclesonide AEROSOL, METERED;NASAL 202129-001 Jan 20, 2012 RX Yes Yes ➤ Subscribe ➤ Subscribe Y ➤ Subscribe
Astrazeneca Pharms ZETONNA ciclesonide AEROSOL, METERED;NASAL 202129-001 Jan 20, 2012 RX Yes Yes ➤ Subscribe ➤ Subscribe Y Y ➤ Subscribe
Applicant Tradename Generic Name Dosage NDA Approval Date TE Type RLD RS Patent No. Patent Expiration Product Substance Delist Req. Exclusivity Expiration

This preview shows a limited data set. Subscribe for full access, or try a Free Trial

Expired US Patents for ZETONNA

Applicant Tradename Generic Name Dosage NDA Approval Date Patent No. Patent Expiration
Astrazeneca Pharms ZETONNA ciclesonide AEROSOL, METERED;NASAL 202129-001 Jan 20, 2012 ➤ Subscribe ➤ Subscribe
Astrazeneca Pharms ZETONNA ciclesonide AEROSOL, METERED;NASAL 202129-001 Jan 20, 2012 ➤ Subscribe ➤ Subscribe
Astrazeneca Pharms ZETONNA ciclesonide AEROSOL, METERED;NASAL 202129-001 Jan 20, 2012 ➤ Subscribe ➤ Subscribe
Astrazeneca Pharms ZETONNA ciclesonide AEROSOL, METERED;NASAL 202129-001 Jan 20, 2012 ➤ Subscribe ➤ Subscribe
Astrazeneca Pharms ZETONNA ciclesonide AEROSOL, METERED;NASAL 202129-001 Jan 20, 2012 ➤ Subscribe ➤ Subscribe
Astrazeneca Pharms ZETONNA ciclesonide AEROSOL, METERED;NASAL 202129-001 Jan 20, 2012 ➤ Subscribe ➤ Subscribe
Applicant Tradename Generic Name Dosage NDA Approval Date Patent No. Patent Expiration

This preview shows a limited data set. Subscribe for full access, or try a Free Trial

Non-Orange Book US Patents for ZETONNA

For Orange Book-listed patents (shown in the main table above) generic applications must certify that the listed patents are expired, invalid, or will not be infringed by generic entry.

The non-Orange Book patents listed below do not require formal certifications, so they do not automatically impede generic entry. Instead, they represent potential opportunities for branded firms to block generic entry through patent infringment challenges.

Patent No. Title Estimated Patent Expiration
5,290,539 Device for delivering an aerosol ➤ Subscribe
6,030,682 Container for aerosol formulation ➤ Subscribe
Patent No. Title Estimated Patent Expiration

This preview shows a limited data set. Subscribe for full access, or try a Free Trial

International Patents for ZETONNA

Country Document Number Estimated Expiration
Australia 7496298 ➤ Subscribe
Canada 2538419 ➤ Subscribe
Austria A176991 ➤ Subscribe
Brazil 9809448 ➤ Subscribe
Japan 6087882 ➤ Subscribe
Spain 2452691 ➤ Subscribe
Japan 3292928 ➤ Subscribe
Brazil 1100860 ➤ Subscribe
Greece 1001529 ➤ Subscribe
Japan 3260752 ➤ Subscribe
Country Document Number Estimated Expiration

This preview shows a limited data set. Subscribe for full access, or try a Free Trial

Supplementary Protection Certificates for ZETONNA

Supplementary Protection Certificate SPC Country SPC Expiration SPC Description
2005 00036 Denmark ➤ Subscribe
C022/2005 Ireland ➤ Subscribe SPC022/2005, 20060612, EXPIRES: 20190415
2005006 Lithuania ➤ Subscribe PRODUCT NAME: CICLESONIDUM (11BETA,16ALFA)-16,17-(((R)-CIKLOHEKSILMETILEN)BIS(OKSI))-11-HIDROKSI-21-(2-METIL-1OKSOPROPOKSI)PREGNA-1,4-DIEN-3,20-DIONAS; REGISTRATION NO/DATE: LT/1/05/0181/001, LT/1/05/0181/002, LT/1/05/0181/003 20050321
2005006,C0983058 Lithuania ➤ Subscribe PRODUCT NAME: CICLESONIDUM (11BETA,16ALFA)-16,17-(((R)-CIKLOHEKSILMETILEN)BIS(OKSI))-11-HIDROKSI-21-(2-METIL-1OKSOPROPOKSI)PREGNA-1,4-DIEN-3,20-DIONAS; REGISTRATION NO/DATE: LT/1/05/0181/001, LT/1/05/0181/002, LT/1/05/0181/003 20050321
Supplementary Protection Certificate SPC Country SPC Expiration SPC Description

This preview shows a limited data set. Subscribe for full access, or try a Free Trial

For more information try a trial or see the plans and pricing

Serving leading biopharmaceutical companies globally:

QuintilesIMS
McKesson
Novartis
Johnson and Johnson
Cipla
Accenture
Medtronic
Teva
Dow

Drugs may be covered by multiple patents or regulatory protections. All trademarks and applicant names are the property of their respective owners or licensors. Although great care is taken in the proper and correct provision of this service, thinkBiotech LLC does not accept any responsibility for possible consequences of errors or omissions in the provided data. The data presented herein is for information purposes only. There is no warranty that the data contained herein is error free. thinkBiotech performs no independent verifification of facts as provided by public sources nor are attempts made to provide legal or investing advice. Any reliance on data provided herein is done solely at the discretion of the user. Users of this service are advised to seek professional advice and independent confirmation before considering acting on any of the provided information. thinkBiotech LLC reserves the right to amend, extend or withdraw any part or all of the offered service without notice.

botpot